Literature DB >> 7570969

Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCV-infected kidney.

A Widell1, S Månsson, N H Persson, H Thysell, S Hermodsson, I Blohme.   

Abstract

Hepatitis C virus (HCV) genotypes, determined by polymerase chain reaction with type-specific primers, were studied in 5 already HCV-infected patients receiving kidneys from HCV-infected cadaver donors. Three patients were investigated retrospectively using stored pre- and posttransplantation sera and followed 18-28 months after transplantation. Two recipients with HCV genotype 2b infection had received kidneys from 1 genotype 3a-infected donor. In 1 recipient, HCV 2b was replaced by the donor's type; in the other recipient, a prolonged mixed infection of 3a and 2b occurred. Persistent alanine aminotransferase (ALT) elevation (3- to 5-fold) appeared in both patients. The third patient, also HCV 2b infected when transplanted with an HCV 3a-infected kidney, remained infected with HCV 2b only. Two patients, one with HCV genotype 1b and the other with genotype 3a, were followed prospectively with frequent bleeds (initially biweekly) and genotyping over 14 months after they had received kidneys from 1 HCV genotype 1a-infected donor. The HCV 1b-infected recipient remained infected with 1b only and had minimal biochemical signs of liver injury. In the other recipient, mixed infection of 3a and 1a appeared at week 3 and persisted for several weeks, until only genotype 1a could be detected. This patient had elevated ALT levels before transplantation. After onset of mixed infection, ALT levels increased further for several weeks, and returned to pretransplantation levels when only HCV 1a was found. HCV-infected kidneys transplanted into HCV-infected recipients gave 3 different virus patterns. Most patients benefitted in the short term, but some super-infected patients experienced increased liver damage.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7570969     DOI: 10.1097/00007890-199510150-00004

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  16 in total

Review 1.  Management of hepatitis C in patients with chronic kidney disease.

Authors:  Mohammad A B Al-Freah; Zeino Zeino; Michael A Heneghan
Journal:  Curr Gastroenterol Rep       Date:  2012-02

2.  KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2018-09-19

Review 3.  Hepatic disorders in chronic kidney disease.

Authors:  Fabrizio Fabrizi; Piergiorgio Messa; Carlo Basile; Paul Martin
Journal:  Nat Rev Nephrol       Date:  2010-04-13       Impact factor: 28.314

Review 4.  Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.

Authors:  Evan B Cunningham; Tanya L Applegate; Andrew R Lloyd; Gregory J Dore; Jason Grebely
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-03-17       Impact factor: 46.802

Review 5.  Hepatitis C and kidney disease: An overview and approach to management.

Authors:  Ahmad Najib Azmi; Soek-Siam Tan; Rosmawati Mohamed
Journal:  World J Hepatol       Date:  2015-01-27

6.  Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection.

Authors:  Jason Grebely; Son Truong Pham; Gail V Matthews; Kathy Petoumenos; Rowena A Bull; Barbara Yeung; William Rawlinson; John Kaldor; Andrew Lloyd; Margaret Hellard; Gregory J Dore; Peter A White
Journal:  Hepatology       Date:  2012-02-29       Impact factor: 17.425

7.  Serological determination of hepatitis C virus subtypes 1a, 1b, 2a, 2b, 3a, and 4a by a recombinant immunoblot assay.

Authors:  M Schröter; H H Feucht; P Schäfer; B Zöllner; R Laufs
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

8.  Progression of fibrosis during chronic hepatitis C is associated with rapid virus evolution.

Authors:  Xiao-Hong Wang; Dale M Netski; Jacquie Astemborski; Shruti H Mehta; Michael S Torbenson; David L Thomas; Stuart C Ray
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

Review 9.  Hepatitis C and its impact on renal transplantation.

Authors:  Jose M Morales; Fabrizio Fabrizi
Journal:  Nat Rev Nephrol       Date:  2015-02-03       Impact factor: 28.314

10.  Treatment of hepatitis C in hemodialysis patients using pegylated interferon alpha-2a in Turkey.

Authors:  Sukran Kose; Alp Gurkan; Fatih Akman; Mehmet Kelesoglu; Ufuk Uner
Journal:  J Gastroenterol       Date:  2009-03-11       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.